CCR5 and metabolic dysfunction-associated steatohepatitis: The dual CCR2/CCR5 inhibitor CVC is currently being tested in patients with NASH and fibrosis [17], based on the evidence from mouse models that CCR2+ monocytes promote fibrogenesis [5,6,21,22].